These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 19690820)

  • 41. Lessons for Medicare Part D in the hemodialysis community.
    Nayeem AI; Chertow GM
    BMC Nephrol; 2006 Jul; 7():11. PubMed ID: 16824211
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population.
    Deitelzweig SB; Pinsky B; Buysman E; Lacey M; Makenbaeva D; Wiederkehr D; Graham J
    Clin Ther; 2013 Oct; 35(10):1536-45.e1. PubMed ID: 24075151
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 2007 costs and coverage of antiretrovirals under Medicare Part D for people with HIV/AIDS living in North Carolina.
    Sengupta S
    N C Med J; 2008; 69(1):6-13. PubMed ID: 18429558
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors.
    Neuman P; Strollo MK; Guterman S; Rogers WH; Li A; Rodday AM; Safran DG
    Health Aff (Millwood); 2007; 26(5):w630-43. PubMed ID: 17711865
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of reaching the drug benefit threshold on Medicare members' healthcare utilization during the first year of Medicare Part D.
    Raebel MA; Delate T; Ellis JL; Bayliss EA
    Med Care; 2008 Oct; 46(10):1116-22. PubMed ID: 18815534
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
    Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
    Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes and costs of patients with persistent asthma treated with beclomethasone dipropionate hydrofluoroalkane or fluticasone propionate.
    Lage MJ; Gross GN; Brewster C; Spalitto A
    Adv Ther; 2009 Aug; 26(8):762-75. PubMed ID: 19669630
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA.
    Kennedy J; Dipzinski A; Roll J; Coyne J; Blodgett E
    Drug Alcohol Depend; 2011 Apr; 114(2-3):201-6. PubMed ID: 21134724
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hospital readmissions in US atrial fibrillation patients: occurrence and costs.
    Amin AN; Jhaveri M; Lin J
    Am J Ther; 2013; 20(2):143-50. PubMed ID: 23183097
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Healthcare utilization and expenditures in patients with atrial fibrillation treated with catheter ablation.
    Ladapo JA; David G; Gunnarsson CL; Hao SC; White SA; March JL; Reynolds MR
    J Cardiovasc Electrophysiol; 2012 Jan; 23(1):1-8. PubMed ID: 21777324
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Medicare Part D in 2008: rising prices and growing confusion.
    Flaer PJ; Younis MZ; Hussain AA; Malow RM
    J Health Care Finance; 2008; 34(4):89-92. PubMed ID: 21110483
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy.
    Dasta JF; Pilon D; Mody SH; Lopatto J; Laliberté F; Germain G; Bookhart BK; Lefebvre P; Nutescu EA
    J Med Econ; 2015; 18(12):1041-9. PubMed ID: 26201251
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D.
    Frankenfield DL; Weinhandl ED; Powers CA; Howell BL; Herzog CA; St Peter WL
    Am J Kidney Dis; 2012 May; 59(5):670-81. PubMed ID: 22206743
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medicare Prescription Drug Plan Enrollees Report Less Positive Experiences Than Their Medicare Advantage Counterparts.
    Elliott MN; Landon BE; Zaslavsky AM; Edwards C; Orr N; Beckett MK; Mallett J; Cleary PD
    Health Aff (Millwood); 2016 Mar; 35(3):456-63. PubMed ID: 26953300
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The costs of atrial fibrillation in patients with cardiovascular comorbidities--a longitudinal analysis of German health insurance data.
    Reinhold T; Lindig C; Willich SN; Brüggenjürgen B
    Europace; 2011 Sep; 13(9):1275-80. PubMed ID: 21515590
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beneficiaries with cardiovascular disease and thePart D coverage gap.
    Polinski JM; Shrank WH; Glynn RJ; Huskamp HA; Roebuck MC; Schneeweiss S
    Circ Cardiovasc Qual Outcomes; 2012 May; 5(3):387-95. PubMed ID: 22511746
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of dronedarone use in the US patient population between 2009 and 2010: a descriptive study using a claims database.
    Gao S; Juhaeri J; Schiappacasse HA; Koren AT; Dai WS
    Clin Ther; 2011 Oct; 33(10):1483-1490.e3. PubMed ID: 21959260
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
    Tseng CW; Brook RH; Keeler E; Mangione CM
    JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Decreasing out-of-pocket costs of antibiotics: the good, the bad, and the unknown.
    Hersh AL; Gonzales R
    Arch Intern Med; 2010 Aug; 170(15):1314-6. PubMed ID: 20696954
    [No Abstract]   [Full Text] [Related]  

  • 60. Healthcare cost attributable to recently-diagnosed breast cancer in a privately-insured population in the United States.
    Fu AZ; Jhaveri M
    J Med Econ; 2012; 15(4):688-94. PubMed ID: 22397589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.